# PharmaHemp® LABORATORIES

CERTIFICATE OF ANALYSIS No.: 2023-13311

CLIENT

Tenacious Halfway Limited t/a PROVACAN, 11 Shepherd Market
W1J 7PG London, United Kingdom

SAMPLE *

Provacan CBD Balm 900mg / 3%

Sample condition:	SUITABLE	Work order:	2023-107801	Sample received:	03/11/2023
Sample ID:	2344024	Analysis ID:	2023_360	Start of analysis:	03/11/2023
Sample type:	Balm	Method ID:	PHL_RPC_16C	End of analysis:	06/11/2023
Batch No.: *	BA03023293A	Method SOP:	MET-LAB-001-08	Analyst:	Domen Lavriha

* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	< LOQ	n/a	
CBDA	- Cannabidiolic acid	1.975	0.099	
CBGA	- Cannabigerolic acid	0.049	0.015	
CBG	- Cannabigerol	0.044	0.013	
CBD	- Cannabidiol	1.157	0.058	
THCV	- Tetrahydrocannabivarin	n/a	n/a	
CBN	- Cannabinol	< LOQ	n/a	
Δ^9-THC	- Δ-9-Tetrahydrocannabinol	0.055	0.012	
Δ^8-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	0.0400	0.0088	
Δ^9-THCA	- Δ-9-Tetrahydrocannabinolic acid	0.0308	0.0068	
CBV	- Cannabivarin	< LOQ	n/a	
CBCA	- Cannabichromenic acid	0.057	0.013	
CBT	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	< LOQ #	n/a	

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

06/11/2023

Approved by:

mag. Janja Ahej
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate